hearing loss
Sensorion Doses First Patient in Phase I/II Trial of OTOF-Linked Hearing Loss Gene Therapy
One patient in Australia has received SENS-501, and the company expects to complete dosing two other patients by year-end.
There are multiple studies of gene therapies for this form of hereditary deafness underway, but until now, patients have only been treated in one ear.
Regeneron Gene Therapy Restores Hearing in Infant With Genetic Form of Deafness, Data at ASGCT Show
Premium
The 10-month-old patient was treated with DB-OTO, a gene therapy developed by Decibel Therapeutics, which Regeneron acquired last year.
Sensorion Looks to Raise €50.5M Through Reserved Offering
The company will use the funds to further develop precision medicines for hearing disorders, including a gene therapy for deafness caused by OTOF mutations.
After Promising Early Efficacy, Eli Lilly Eager to Study Hearing Loss Gene Therapy in More Children
Premium
So far two patients, ages 8 and 11, have been enrolled in the Phase I/II trial of AK-OTOF, a gene therapy candidate from Lilly subsidiary Akouos.